The optimal pharmacological formula for percutaneous coronary intervention

Bibliography

• Smith SC Jr, Dove JT, Jacobs AK, ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) – executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019-41
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Feldman TE, Hirshfeld JW Jr, ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation 2006;113:156-75
   PubMed Web of Science ®Google Scholar
• King SB III, Smith SC Jr, Hirshfeld JW Jr, 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 Writing Committee. Circulation 2008;117:261-95
   PubMed Web of Science ®Google Scholar
• Kushner FG, Hand M, Smith SC Jr, 2009 focused updates: ACC/AHA guidelines for the management of patients with st-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT III, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95:1218-22
   PubMed Web of Science ®Google Scholar
• Mehta SR, Bassand JP, Chrolavicius S, ; CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, ; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9
   PubMed Web of Science ®Google Scholar
• Bennett CL, Davidson CJ, Raisch DW, Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159:2524-8
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Taubert D, Pogatsa-Murray G, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005;112:2946-50
   PubMed Web of Science ®Google Scholar
• Patti G, Colonna G, Pasceri V, A randomized trial of high loading dose of clopidogrel for reduction of peri-procedural myocardial infarction in patients undergoing coronary intervention results from the ARMYDA-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 2005;111:2099-106
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Angiolillo DJ, Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 2009;157:818-24
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Brennan DM, ; CREDO Investigators. Optimal timing for the initiation of pretreatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939-43
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Frundi D, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Suryadevara S, Capranzano P, Bass TA. Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother 2008;9:2893-900
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• O'Donoghue M, Antman EM, Braunwald E, The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38) analysis. J Am Coll Cardiol 2009;54:678-85
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-36
   PubMed Web of Science ®Google Scholar
• Montalescot G, Wiviott SD, Braunwald E, Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31
   PubMed Web of Science ®Google Scholar
• Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010;8:151-8
   PubMedGoogle Scholar
• Wallentin L, Becker RC, Budaj A, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41
   PubMed Web of Science ®Google Scholar
• Berger JS, Roe MT, Gibson CM, Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the early rapid reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) pilot trial. Am Heart J 2009;158:998-1004
   PubMed Web of Science ®Google Scholar
• Leonardi S, Rao SV, Harrington RA, Rationale and design of the randomized, double-blind trial testing intravenous and oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-PCI). Am Heart J 2010;160:65-72
   PubMed Web of Science ®Google Scholar
• Gurm H, Tamhane U, Meier P, A comparison of abciximab and small molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Intervent 2009;2:230-6
   PubMedGoogle Scholar
• De Luca G, Ucci G, Cassetti E, Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009;53:1668-73
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Percoco G, Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008;299:1788-99
   PubMed Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Schulz S, Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009;119:1933-40
   PubMed Web of Science ®Google Scholar
• Van't Hof AW, Ten Berg J, Heestermans T, Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind, randomised controlled trial. Lancet 2008;372:537-46
   PubMed Web of Science ®Google Scholar
• Hamm C. On-TIME 2. Presented at the American College of Cardiology 2008 Scientific Sessions; 29 March – 1 April 2008; Chicago, USA
   Google Scholar
• Ellis SG, Tendera M, de Belder MA, Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008;358:2205-17
   PubMed Web of Science ®Google Scholar
• Ferguson JJ, Califf RM, Antman EM, Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kleiman NS, Kereiakes DJ, ; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30
   PubMed Web of Science ®Google Scholar
• Yusuf S, Mehta SR, Chrolavicius S, Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464-76
   PubMed Web of Science ®Google Scholar
• Capranzano P, Capodanno D, Tamburino C. Clinical development of selective anticoagulants: a state of the art. Rev Recent Clin Trials 2010;5:85-93
   PubMedGoogle Scholar
• Cohen M, Bhatt DL, Alexander JH, Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007;115:2642-51
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Antman EM, Widimsky P, Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374:787-95
   PubMed Web of Science ®Google Scholar
• Mega J, Braunwald E, Mohanavelu S, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38
   PubMed Web of Science ®Google Scholar
• Pasceri V, Patti G, Nusca A, Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation 2004;110:674-8
   PubMed Web of Science ®Google Scholar
• Patti G, Pasceri V, Colonna G, Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8
   PubMed Web of Science ®Google Scholar
• Briguori C, Visconti G, Focaccio A, Novel approaches for preventing or limiting events (Naples) II trial. Impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54:2157-63
   PubMed Web of Science ®Google Scholar
• Di Sciascio G, Patti G, Pasceri V, Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Results of the ARMYDA-RECAPTURE trial. J Am Coll Cardiol 2009;54:558-65
   PubMed Web of Science ®Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Lastra-Gonzalez G, Manrique CM, Govindarajan G, Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. Expert Opin Pharmacother 2005;6:2209-21
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010;31:17-28
   PubMed Web of Science ®Google Scholar
• Becker RC, Moliterno DJ, Jennings LK, ; TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;373:919-28
   PubMed Web of Science ®Google Scholar
• Park SJ, Park DW, Kim YH, Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-82
   PubMed Web of Science ®Google Scholar
• O'Donoghue ML, Braunwald E, Antman EM, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97
   PubMed Web of Science ®Google Scholar
• Abraham NS, Hlatky MA, Antman EM, ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010;56:2051-66
   PubMed Web of Science ®Google Scholar